Exosome Therapy Explained: DayZero™ Dosing From 150 Billion to 500 Billion Particles — Complete 2025 Guide

Table of Contents

What Exosome Therapy Is
How Exosomes Work: The Extracellular Vesicle Signaling Mechanism
Types of Exosome Products: Therapeutic vs. Aesthetic Dosing
Conditions Addressed With Exosome Therapy
Who Is a Candidate for Exosome Therapy
What to Expect: Before, During, and After
Results and Realistic Expectations
Costs and What Is Included
The Rebuild Regen Approach: DayZero™ Exosomes
Exosome Therapy vs. Stem Cell Therapy: Choosing the Right Option
Frequently Asked Questions
When Exosome Therapy Is Not the First Choice

What Exosome Therapy Is

Exosome therapy is a regenerative medicine treatment that uses extracellular vesicles, nanoscale signaling particles sourced from perinatal tissue, to deliver repair-triggering micro-RNA, proteins, and lipids to damaged or inflamed tissue.

The name "exosomes" refers to a class of extracellular vesicles (EVs) measuring between 30 and 150 nanometers in diameter. These particles are not cells. They carry no nucleus, cannot replicate independently, and do not grow or divide. What they do carry is a sophisticated molecular payload derived from the cells that produced them.

In clinical applications, exosomes used at Rebuild Regen Medical Clinic come from the DayZero™ line by ZEO ScientifiX, derived from perinatal tissue including umbilical cord and related sources. The production process concentrates the vesicular output of highly active neonatal cells, yielding products with specific, measured particle counts and confirmed biological activity.

This distinction matters immediately: exosome therapy delivers cell-derived signaling molecules without delivering the cells themselves. This creates a unique clinical profile with advantages in certain applications and different considerations in others compared to stem cell therapy.

Elizabeth Celestin, APRN, FNP-C, administers exosome therapy at Rebuild Regen Medical Clinic under established clinical protocols. For applications involving systemic IV delivery or complex multi-modal combinations, the treatment plan involves [MD_PLACEHOLDER] MD oversight.

How Exosomes Work: The Extracellular Vesicle Signaling Mechanism

Exosome therapy works by delivering a concentrated payload of biologically active molecules to target tissues, triggering cellular responses that reduce inflammation, support repair, and modulate gene expression.

What Exosomes Carry

The therapeutic value of exosomes resides in their cargo:

Micro-RNA (miRNA): Short, non-coding RNA sequences that regulate gene expression in recipient cells. When an exosome delivers miRNA to an injured cell, that miRNA can upregulate repair genes and downregulate inflammatory gene expression. This epigenetic influence distinguishes exosomes from simpler growth factor preparations.

Proteins: Exosomes carry growth factors including VEGF, TGF-beta, and FGF, as well as anti-inflammatory cytokines, heat shock proteins that protect cells under stress, and structural proteins that support cell membrane repair.

Lipids: The lipid bilayer of exosomes carries bioactive lipid signaling molecules that interact with cell surface receptors, triggering secondary messenger cascades inside target cells.

How They Reach Target Tissue

When DayZero™ exosomes are administered, either via local injection or intravenous delivery, they circulate and preferentially accumulate at sites of inflammation and injury. The mechanism of targeting is similar to what MSCs use: chemokine gradients produced by damaged tissue draw vesicles toward the injury site. At the surface of target cells, exosomes either fuse with the cell membrane or are taken up via endocytosis, releasing their payload into the cytoplasm.

The result is a reprogramming of local cellular behavior. Damaged tissue moves from a pro-inflammatory, degenerative state toward a repair-permissive, anti-inflammatory state.

Why Particle Count Matters

A single exosome carries a limited payload. The therapeutic effect scales with the number of exosomes delivered. This is why DayZero™ products are measured in billions of particles. At 150 billion particles, you are delivering a volume of signaling molecules sufficient to create a biological effect at a specific target site. At 500 billion particles, the signaling potential is substantially higher, relevant for systemic or high-burden applications.

Dosing is not arbitrary. The clinical decision between 150B, 250B, and 500B products involves assessing the extent of damage, the target tissue area, the delivery method, and whether the application is orthopedic/local or systemic.

Types of Exosome Products: Therapeutic vs. Aesthetic Dosing

The DayZero™ exosome line from ZEO ScientifiX is segmented by particle count and application type.

Therapeutic Exosomes (150B, 250B, 500B)

These are clinical-grade products intended for orthopedic, neurological, and systemic therapeutic applications.

150 Billion Particle Vials: The entry point for therapeutic application. Used for single-joint local injection (knee, shoulder, hip), targeted soft tissue injections, and applications where exosomes are being combined with stem cells or PRP to augment the signaling environment rather than serve as the primary biologic.

250 Billion Particle Vials: Mid-range therapeutic dosing. Appropriate for larger target areas, multi-site applications, or moderate-severity systemic inflammatory protocols. The 250B product is frequently used as the primary exosome delivery in IV protocols targeting neuropathy or systemic anti-inflammatory goals.

500 Billion Particle Vials: The highest therapeutic concentration in the DayZero™ line. Used for high-burden systemic applications, significant neurological conditions, complex multi-system inflammatory presentations, or patients who have not achieved adequate response from lower-dose protocols. Also used in aggressive longevity and cellular health protocols.

Aesthetic Exosomes (25B to 100B)

Lower-particle-count exosome products targeted at skin, scalp, and hair restoration applications. Administered topically or via micro-needling, mesotherapy, or intradermal injection for skin rejuvenation, collagen stimulation, hair follicle support, and wound healing.

The aesthetic exosome applications at Rebuild Regen include scalp and hair restoration protocols and skin rejuvenation protocols designed to improve texture, reduce inflammatory skin conditions, and support post-procedure healing.

Patient Pure X (PPX)

An autologous EV concentrate derived from the patient's own blood, processed via unique centrifugation that concentrates platelet-derived extracellular vesicles. PPX combines the autologous (same patient, no rejection concern) advantage with the EV signaling mechanism. It is positioned as an adjunct or alternative for patients who prefer autologous sourcing, and is frequently combined with PRP protocols.

Wharton's Jelly Matrix

A scaffold product with 50 billion to 200 billion EV payload, derived from Wharton's jelly collagen and hyaluronic acid. Primarily used for joint applications where the collagen/HA scaffold provides structural support alongside the EV signaling component. This combination is particularly relevant for cartilage repair contexts.

Conditions Addressed With Exosome Therapy

Exosome therapy at Rebuild Regen is applied across four primary application areas. Each leverages a different aspect of the exosome signaling mechanism.

Orthopedic and Musculoskeletal

Exosomes are effective in orthopedic applications because the miRNA and growth factor payload directly addresses the key mechanisms driving joint degeneration and soft tissue injury: chronic inflammation, chondrocyte degradation, and impaired collagen synthesis.

Osteoarthritis: Local intra-articular exosome injection reduces the inflammatory cytokine environment in affected joints. chondrocyte protection via miRNA delivery has been studied, showing potential to slow cartilage degradation and improve synovial fluid quality. Exosomes are used as a standalone orthopedic intervention or in combination with DayZero™ stem cells or Wharton's Jelly Matrix for enhanced structural support.

Tendinopathy and ligament injuries: The growth factor payload of therapeutic exosomes supports collagen synthesis in damaged tendon tissue. The LightForce XLi laser and Chattanooga Intelect RPW 2 shockwave therapy are frequently combined with exosome injections in tendon protocols, creating a multi-modal approach that addresses both cellular signaling and mechanical tissue remodeling.

Post-surgical recovery: IV exosome protocols following orthopedic procedures support systemic inflammatory resolution and may accelerate the healing timeline for soft tissue and bone recovery.

Neurological and Neuropathic

The ability of exosomes to cross the blood-brain barrier and deliver neurotrophic factors makes them relevant in neurological applications. DayZero™ exosomes carry BDNF-associated miRNA and anti-neuroinflammatory cargo that supports nerve repair processes.

In neuropathy treatment, exosomes are incorporated into the Rebuild Neuropathy Protocol for patients where the inflammatory component of nerve damage is the primary driver. IV exosome administration at 250B or 500B is combined with Class IV laser therapy, IV nutritional infusions, and hormonal correction as indicated.

Traumatic brain injury support and cognitive health: These are emerging areas of application. Exosomes at high particle counts, delivered IV, are used in some longevity and neurological health protocols. This area is investigational and discussed with full transparency at consultation.

Systemic Anti-Inflammatory and Longevity

IV exosome protocols at 250B to 500B are used for systemic anti-inflammatory burden reduction, particularly in patients with chronic low-grade inflammation contributing to fatigue, cognitive decline, and functional limitation. The mechanism mirrors MSC therapy systemic protocols, delivering immunomodulatory signaling molecules without delivering cells.

The appeal of exosome IV versus MSC IV for some patients includes shorter administration time, no cell viability concerns during storage, and a smaller payload footprint that may suit patients with very active immune systems or specific comorbidities better than full MSC protocols.

Aesthetic: Skin, Scalp, and Hair

Aesthetic exosome applications use lower particle count products (25B to 100B) for skin rejuvenation, hair follicle stimulation, and post-procedure healing support. These are delivered topically with micro-needling enhancement or via direct injection to the scalp for hair restoration protocols.

Who Is a Candidate for Exosome Therapy

Exosome therapy is appropriate for a wide range of patients. The relative simplicity of administration (no cell harvest, shorter procedure time than most biologics) and the absence of a cell-based rejection risk make exosomes accessible to a broad population.

Strong candidates include:

Patients with orthopedic conditions including OA, tendinopathy, and soft tissue injury seeking a biologic boost beyond PRP
Patients who have received stem cell therapy and want to extend or supplement the signaling environment at follow-up
Patients with neuropathy where IV exosome delivery provides systemic neuroinflammatory support
Patients pursuing systemic anti-inflammatory protocols for longevity or chronic fatigue management
Aesthetic candidates for skin rejuvenation or hair restoration

Patients for whom a different protocol may be more appropriate:

Severe structural damage requiring mechanical correction (decompression, surgery)
Conditions requiring the full MSC paracrine signaling spectrum including differentiation capacity, where DayZero™ stem cells are the better choice
Patients with active malignancy (exosomes carry proliferative signaling molecules; oncology clearance required)

Evaluation includes:

Medical history and current condition review
Determination of whether the exosome application is local, IV systemic, or aesthetic
Protocol design and particle count selection
Discussion of combination with PRP, MSCs, laser, shockwave, or nutritional IV support

What to Expect: Before, During, and After

Before Your Exosome Procedure

The process begins with a consultation. Elizabeth Celestin reviews the patient's history, condition, and treatment goals. For most exosome procedures, this consultation guides direct protocol selection. For complex systemic or multi-modal cases, [MD_PLACEHOLDER] MD is involved in the protocol review.

Pre-procedure preparation varies by delivery method. Local injection protocols require minimal preparation. IV infusion protocols may include pre-hydration recommendations and temporary restriction of anti-inflammatory medications.

During the Procedure

Local injection procedure: DayZero™ exosomes are prepared from the vial and administered directly to the target site. Using imaging guidance where appropriate for joint injections, the physician places the exosome product at the optimal location within the target tissue. Procedure time: 20 to 45 minutes depending on the number of injection sites.

IV infusion procedure: The DayZero™ exosome product is introduced via IV drip over 30 to 60 minutes. The patient rests comfortably during administration. Vital signs are monitored throughout.

Aesthetic application: Exosome products are applied topically to the treatment area following micro-needling to enhance absorption, or administered via direct intradermal injection for scalp and hair restoration protocols.

Discomfort is minimal for all delivery methods. IV administration is generally comfortable. Local injections involve standard injection discomfort at the target site.

After the Procedure

Recovery is minimal across all exosome delivery methods. Most patients resume normal activity the same day or the following day.

Local injection post-procedure care includes relative rest of the treated joint for 24 to 48 hours and restriction of anti-inflammatory medications for 48 to 72 hours. IV protocol patients have minimal post-procedure restrictions.

Follow-up is scheduled at 4 to 6 weeks to assess early response and at 3 months for full evaluation.

Results and Realistic Expectations

Exosome therapy initiates biological processes that unfold over a period of weeks to months. The timeline for results shares characteristics with MSC therapy but may show a slightly faster early response in some patients due to the concentrated signaling payload without the additional time required for MSC homing and establishment.

Typical timeline:

Weeks 1 to 3: Anti-inflammatory signaling begins. Some patients report early reduction in pain levels and swelling.
Weeks 4 to 8: Tissue repair processes are active. Orthopedic patients often report improved range of motion and reduced pain with activity.
Months 2 to 4: The most significant improvements for orthopedic and neuropathic patients. The miRNA influence on local gene expression consolidates into observable tissue changes.
Months 4 to 6: Response plateau for most patients. Decisions about follow-up dosing are made at the 3-month appointment.

Factors influencing results:

Particle count administered (higher count = stronger signal)
Delivery method (IV systemic vs. local injection)
Severity and chronicity of the underlying condition
Patient baseline health and anti-inflammatory lifestyle factors
Whether exosome therapy is used as a standalone intervention or combined with PRP, stem cells, laser, or shockwave

What is realistic to expect:

Orthopedic patients with knee OA typically report 40 to 60 percent pain reduction by month 3 to 4 with therapeutic exosome injection protocols.
Neuropathy patients receiving IV exosome protocols combined with laser therapy and nutritional support report reduction in burning and tingling sensations over 8 to 12 weeks.
Aesthetic patients typically see initial skin quality improvements at 4 to 6 weeks, with full results at 3 months.
No outcome is guaranteed. Individual variation is real, and the consultation process sets realistic expectations before any protocol is initiated.

Costs and What Is Included

Exosome therapy pricing reflects the particle count of the DayZero™ product selected, the delivery method, and whether the application is therapeutic or aesthetic.

General pricing structure:

Lower particle count products (150B) for localized injection applications: lower price tier
Higher particle count products (500B) for systemic IV or complex applications: higher price tier
Aesthetic applications (25B to 100B): separate aesthetic pricing tier

Exact pricing is provided at consultation after protocol selection. All pricing is transparent before any treatment decision.

Included in the therapeutic protocol fee:

Elizabeth Celestin consultation and clinical management
DayZero™ exosome product (particle count per protocol)
Procedure administration and monitoring
Follow-up appointments at 4 to 6 weeks and 3 months

Exosome therapy is not covered by insurance. Medical financing is available.

The Rebuild Regen Approach: DayZero™ Exosomes

Rebuild Regen Medical Clinic uses DayZero™ exosomes exclusively from ZEO ScientifiX, the same supplier providing the DayZero™ stem cell line. This integration creates a coherent biologic protocol system where stem cell therapy and exosome therapy are sourced from the same manufacturing standards and can be reliably combined.

The DayZero™ exosome line is:

Derived from perinatal tissue (umbilical cord and related sources)
AABB-accredited manufacturing chain
Particle count confirmed per lot with COA
FDA-registered product under 21 CFR Part 1271
Available in three therapeutic particle counts (150B, 250B, 500B) and aesthetic range (25B to 100B)

The consistency of sourcing matters for combination protocols. When a patient receives both DayZero™ MSCs and DayZero™ exosomes in the same session, the clinic is working with verified products from the same quality system, not mixing products from different manufacturers with different standards.

Elizabeth Celestin's experience administering exosome protocols means that product selection and combination design is based on clinical outcomes from real patient populations, not theoretical framework alone. The clinical protocols at Rebuild Regen have been refined based on what actually produces results in the South Florida patient population: largely active adults 45 and older with orthopedic, hormonal, and age-related health goals.

Exosome Therapy vs. Stem Cell Therapy: Choosing the Right Option

Exosome therapy and stem cell therapy are not competing options. They operate through related but distinct mechanisms and are frequently combined. Understanding the differences guides the decision about which to prioritize in a given clinical situation.

Choose exosome therapy when:

The primary therapeutic need is signaling (gene expression regulation, anti-inflammatory modulation, trophic support) without the full cellular infrastructure of live MSCs
The patient prefers a slightly shorter procedure with no live cell administration
The condition responds well to high-concentration signaling (inflammation-driven OA, systemic neuroinflammation, aesthetic applications)
Exosomes serve as an adjunct to stem cell therapy, extending the signaling duration post-MSC administration
Budget considerations favor the exosome-first approach with stem cells reserved for follow-up if needed

Choose stem cell therapy when:

The condition benefits from the full MSC paracrine toolkit including differentiation capacity
The patient requires the homing and establishment behavior that live MSCs provide
Systemic immune modulation at the cellular level is the primary goal
The clinical picture warrants the most comprehensive biologic intervention available

Both together: Combined protocols are common at Rebuild Regen. DayZero™ MSCs and DayZero™ exosomes administered in the same session deliver both the cellular and vesicular components of the regenerative signal. This combination is used for high-priority orthopedic cases, significant systemic inflammatory presentations, and patients seeking comprehensive cellular health optimization.

Frequently Asked Questions

What are exosomes and how are they different from stem cells?

Exosomes are extracellular vesicles, nanoscale particles secreted by cells. They are not cells themselves. Stem cells are living cells capable of self-renewal and differentiation. Exosomes carry the signaling cargo of stem cells (miRNA, proteins, lipids) without the cellular structure. Both reduce inflammation and support tissue repair, but through different biological processes. Stem cells home to injury sites and establish there; exosomes deliver their payload and are absorbed by recipient cells without establishing residency.

How many exosome particles do I need?

The appropriate particle count depends on the application. Localized orthopedic injections for a single joint are typically addressed with 150 billion particles. Systemic IV protocols and more extensive applications use 250 to 500 billion particles. The treating provider determines the appropriate dose at consultation based on the condition, target area, and clinical context.

Are exosomes FDA-approved?

Exosome products are regulated as human cellular and tissue products (HCT/Ps) under FDA 21 CFR Part 1271. The FDA has not approved any exosome product as a drug therapy for a specific condition. DayZero™ exosomes are FDA-registered under the HCT/P framework. This means they meet manufacturing standards for human tissue products. The distinction between FDA registration and drug approval is explained fully at consultation.

Is there a risk of rejection with exosome therapy?

Exosomes do not carry cell surface antigens in the same way that cells do, which means the rejection risk associated with allogeneic cell transplant is substantially lower. Adverse immune reactions to exosome therapy are rare. The product's perinatal origin and the manufacturing process used by ZEO ScientifiX further reduce immunogenicity risk. Informed consent covers all known adverse reaction possibilities.

How long does an exosome therapy session take?

Local injection protocols take 20 to 45 minutes including preparation. IV exosome infusion sessions run 30 to 60 minutes. Aesthetic exosome procedures with micro-needling enhancement run 45 to 60 minutes.

Can exosome therapy treat neuropathy?

Exosome therapy addresses the neuroinflammatory component of peripheral neuropathy. IV exosome protocols at 250B to 500B deliver neurotrophic miRNA and anti-inflammatory cytokines that support nerve repair processes. Exosomes are incorporated into the Rebuild Neuropathy Protocol for appropriate candidates, combined with Class IV laser therapy, nutritional IV infusions, and other modalities. Exosomes reduce ongoing inflammatory nerve damage and support viable nerve tissue. Complete reversal of advanced nerve damage is not achievable with any current intervention.

How is exosome therapy different from PRP?

Platelet-rich plasma (PRP) concentrates platelets from the patient's own blood, delivering growth factors (PDGF, EGF, TGF-beta) to the injection site. Exosome therapy delivers a different payload: miRNA for gene expression regulation, a broader cytokine profile, and a systemic delivery capacity (via IV) that PRP does not offer. PRP is autologous and lower cost; exosome therapy offers a more complex signaling mechanism with systemic reach. The two are frequently combined in protocols.

Can exosome therapy help with hair loss?

Exosome therapy supports hair follicle function via growth factor delivery and anti-inflammatory signaling at the scalp. DayZero™ aesthetic exosome products in the 25B to 100B range are applied via micro-needling or direct scalp injection. Patients with androgenic alopecia and inflammatory scalp conditions see the strongest response. Hair restoration protocols are discussed at consultation.

How soon after exosome therapy can I exercise?

Local injection sites require 24 to 48 hours of activity restriction to avoid mechanical disruption of the product at the target site. IV exosome protocols have minimal activity restrictions post-procedure. Light activity is typically resumed the day after treatment; more intense exercise is cleared at 48 to 72 hours.

Does exosome therapy replace stem cell therapy?

Exosome therapy and stem cell therapy are complementary, not interchangeable. Each has clinical contexts where it performs best. For patients who have had stem cell therapy, exosome therapy can extend and reinforce the signaling effect. For patients new to regenerative medicine, the choice between protocols is made at consultation based on clinical needs, goals, and budget.

When Exosome Therapy Is Not the First Choice

Exosome therapy is an effective biologic intervention, but there are conditions and circumstances where a different approach is more appropriate as the first-line treatment.

Structural mechanical conditions: When joint pain is driven by mechanical instability, bone-on-bone degeneration, or disc herniation requiring physical decompression, exosome therapy addresses the inflammatory component but cannot correct the mechanical deficit. Knee on Trac decompression, Antalgic-Trac spinal decompression, or surgical intervention may need to precede or accompany biologic treatment.

Conditions better served by stem cells first: When the clinical picture calls for the full cellular toolkit of live MSCs, including higher differentiation potential, the established homing behavior of living cells, and the broader signaling cascade associated with MSC paracrine activity, DayZero™ stem cell therapy is the primary recommendation. Exosomes can augment or follow, but should not substitute for stem cells in cases where cell-level intervention is clinically appropriate.

Acute injuries in the early healing phase: Very recent injuries are often managed best with conservative care, PRP, or rest before introducing exosome therapy. The biological environment in the first days after acute trauma is already rich with native repair signals, and timing of exosome administration affects outcome. The consultation determines the appropriate window.

Active malignancy: Exosomes carry proliferative signaling molecules including growth factors that could theoretically support tumor activity. Oncology clearance is required before exosome therapy is scheduled for any patient with active cancer or recent cancer history.

Schedule a consultation: (954) 953-4208 | Rebuild Regen Medical Clinic, 3320 N Federal Hwy #101, Lighthouse Point, FL 33064.